The history of the study of proteolytic enzymes (peptidases) can be traced back at least to the late eighteenth century, but in recent times the work has accelerated greatly, fuelled by numerous practical applications in biotechnology, and the realization that these enzymes are major therapeutic targets. Notably, the success of inhibitors of angiotensin converting enzymes for the treatment of hypertension, and retropepsin in the treatment of AIDS has provided an unambiguous validation of the principle that peptidase inhibitors can be successful drugs. The many ways in which proteolytic enzymes impinge on the health and welfare of mankind have made it essential for biological scientists to have ready access to data on peptidases, but the she...